US President Donald Trump has been infected with the Corona virus. (File Photo)
US President Donald Trump has become Corona positive. He is running at Walter Reed Army Hospital. Trump is being given a dose of experimental Ebola drug Remdesivir.
The National Institutes of Health found that people who were given doses of Remedisvir on average had been discharged from the hospital in 11 days. On average, Corona patients are recovering four days before this drug. The FDA has allowed emergency use of this antiviral drug being sold by Gilead Sciences Inc.
On average, patients are recovering four days before this medicine
According to scientists, the US-based pharmaceutical company Gilead’s Remedesivir drug is not designed to treat corona virus infection. Although patients are benefiting from this drug. Research is still to be done on the side effects of this medicine. Earlier, it was proved to be very beneficial for the critically ill people of John Hopkins University by mixing it with other medicines.Also Read: 48 Hours Important for Donald Trump, Chief of Staff said- ‘Condition is very worrying’
In the US, an 89-year-old pizza delivery boy received Rs 9 lakh as a tip
The FDA allowed this drug on May 1 of this year. The NIH had earlier released a study on the use of this drug in late April. According to this research, this drug helps in improving the relative speed of Remedisvir by 31%. This drug works by preventing the virus from copying itself into a patient’s body, so it cannot spread further but scientists have not yet detected it, how is this possible? The President was also given an experimental antidote to Regeneron before being admitted to the hospital.
Use of this medicine in China has no side effects
Not only America, it is being treated in many hospitals around the world. Although this drug was previously used in China on seriously ill patients, which had no effect. Now its new trial was done by the US National Institute of Allergy and Infectious Diseases. Trump’s adviser, US health officer Dr Anthony Focky, described the fast-looking reform as ‘good news’.
